Award of Phase 3 Contracts

We are pleased to announce that of the ten Contractors that successfully completed Phase 2, eight have now been awarded Specific Contracts for Phase 3 to complete testing and integration of the innovative NGS workflows.

Phase 3 commenced in April 2024 and will end in May 2025.

Further details can be found under Phase 3 – Testing and Integration

Selected Contractors:

Lot 1: Pre-Sequencing 

Lead: QIAGEN GmbH
 
TwistPlatomicsMGI – Project abstract
Lead: Twist Bioscience Corporation
 
 

Lot 3: Bioinformatics Analysis

Congenica L3 – Project abstract
Lead: Congenica Limited BIC Wellcome Genome Campus
Consortium members: Single tenderer
 
Cancer Analysis GPAP – Project abstract
Lead: FUNDACIO CENTRE DE REGULACIO GENOMICA
Consortium members: Single tenderer
PlatoDKFZCharité – Project abstract 
Lead: Platomics GmbH
Consortium members: Deutsches Krebforschungszentrum, Charité Universitätsmedizin Berlin
 

Lot 4: Integrated Reporting

Cancer Reporting GPAP – Project abstract
Lead: FUNDACIO CENTRE DE REGULACIO GENOMICA
Consortium members: Single tenderer
 
Congenica L4 – Project abstract
Lead: Congenica Limited BIC Wellcome Genome Campus
Consortium members: Single tenderer
 
EU Onco Platform L4 – Project abstract
Lead: BC Platforms AG
Consortium members: Euformatics Oy, Oncompass Medicine Hangary Kft.
Previous Story

Event Announcement: NGS for Precision Medicine and Pharmacogenomics in Cancer